BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Yahoo! Finance
Under the terms of the agreement, BioMarin will pay cash for all of Amicus' shares for a total consideration of $4.8bn. This deal will set BioMarin back $14.50 per share, constituting a 33% premium on Amicus' $10.89 18 December stock value at market close. BioMarin's stock has increased 17.71% on the acquisition, from an 18 December close of $51.95 to a 19 December close of $61.15. This multi-billion-dollar deal, which is the biggest in BioMarin's history, will give the pharma rights to Amicus' Fabry disease therapy, Galafold (migalastat), which has been on the US market since 2018. In 2024, the drug brought in $458.1m for Amicus, an 18% increase on 2023. Galafold is currently the only US Food and Drug Administration (FDA) approved chaperone therapy for Fabry disease – a rare genetic disorder characterised by the buildup of fatty substrates in the cells of an affected patient. Following a US patent litigation with generics giant Teva Pharmaceuticals, Galafold now holds market
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- A $4.8 Billion Reason to Buy BioMarin Stock Today [Yahoo! Finance]Yahoo! Finance
- BioMarin: Amicus Buyout Sparks My Enthusiasm [Seeking Alpha]Seeking Alpha
- BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target raised by analysts at HC Wainwright from $55.00 to $60.00. They now have a "neutral" rating on the stock.MarketBeat
- These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More [Yahoo! Finance]Yahoo! Finance
BMRN
Earnings
- 10/27/25 - Miss
BMRN
Sec Filings
- 12/22/25 - Form 8-K
- 12/19/25 - Form 8-K
- 12/17/25 - Form 8-K
- BMRN's page on the SEC website